FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2576506429> ?p ?o ?g. }

• W2576506429 abstract "Abstract BACKGROUND: Despite excellent outcomes in pediatric ALL, 20-30% of patients relapse or become refractory to frontline therapies with subsequent CR2 rates of only 60%. For multiply relapsed patients, response rates remain around 40%, with <10% overall survival in third complete response.(Gaynon, BJH 2005) In pediatric AML, five-year overall survival remains around 60% among children and adolescents but with a very poor prognosis for relapsed or refractory AML (<20% three-year OS).(Wells, JCO 2003) Clearly, novel combinations with improved complete response rates and long term outcomes are needed for these high risk patients. Several studies have supported the rationale for using either Clofarabine or Mitoxantrone in patients with refractory/relapsed acute leukemia.(Wells, JCO 2003; Jeha, JCO 2009) Mitoxantrone and clofarabine as single agents, have proven effective in children with relapsed/refractory ALL and AML and offer possible synergistic activity in vivo with less drug resistance. (Chow, Leukemia & Lymphoma 2000) OBJECTIVES: To determine the maximal tolerated dose and overall response rate of clofarabine in combination with mitoxantrone as reinduction therapy for refractory/relapsed acute leukemia. To determine the percent of minimal residual disease (MRD) following reinduction with mitoxantrone and clofarabine reinduction therapy.To further characterize the biology of childhood, adolescent and young adult refractory/relapsed acute leukemia. DESIGN: Prospective, multi-center, treatment-based, non-randomized, open label, uncontrolled, single group assignment, safety and efficacy study (phase I/II). Patients 0-30.99yr old with ALL, AML or NHL in 1st, 2nd or 3rd relapse OR primary induction failure were given 1 to 3 cycles of clofarabine (escalating doses 20, 30, 35 and 40mg/m2/day) Day 1-5, in combination with mitoxantrone 12mg/m2/day on Day 3-6. Dexrazoxane was given prior to Mitoxantrone. Dose escalation was planned every 3 patients pending dose limiting toxicities. CNS prophylaxis was achieved with intrathecal liposomal cytarabine. (Figure 1) Patients were allowed subsequent cycles pending response and anthracycline exposure. RESULTS: To date 15 patients have been enrolled on the safety portion of this study. Median Age is 16yrs (8months-23yrs); 9 ALL (3=Induction Failure, 4=Relapse1, 2=Relapse2), 5 AML (4=Induction Failure, 1=Relapse2), 1 NHL (=Progressive Disease). There have been 2 prolonged Grade III/IV toxicities at Dose Level 4 (Clofarabine 40mg/m2) (1 hepatic toxicity, 1 prolonged myelosuppression) hence we are currently enrolling at Dose Level 3 (Clofarabine 35mg/m2). Median time to neutrophil recovery is 24 days. Twelve of 14 (86%) evaluable leukemia patients achieved a CR after 1 cycle of therapy. Of these patients, 92% achieved MRD negativity (<0.1%). Two patients with relapsed ALL had no response. One patient with relapsed/refractory NHL had progressive disease after 2 cycles. Eleven of 12 patients achieving CR went on to receive an allogeneic HSCT with continued remission at a median follow up time of 224 days (range 31-593). CONCLUSION: The combination of clofarabine and mitoxantrone reinduction therapy for relapsed or refractory acute leukemia appears to be safe and well tolerated in children, adolescents and young adults with poor risk hematologic malignancies. The MTD or tolerable dose of this combination has yet to be reached. Hematopoietic recovery appears to be rapid and complete. Initial data from the first 15 patients enrolled is encouraging with an 86% CR rate in leukemic patients. Once the MTD or tolerable dose is reached, an extended multicenter Phase II Study will be initiated. Table 1. Treatment Schema DAY 1 2 3 4 5 6 7 8 21 CLOFARABINE ● ● ● ● ● DEXRAZOXANE ● ● ● ● MITOXANTRONE ● ● ● ● DEXAMETHASONE ● ● ● ● ● IT LIPOSOMAL ARAC ● FILGASTRIM (…continued until ANC > 1500/mm3 x 2 consecutive days) ● → → Disclosures No relevant conflicts of interest to declare." @default.
• W2576506429 created "2017-01-26" @default.
• W2576506429 creator A5001697191 @default.
• W2576506429 creator A5005741602 @default.
• W2576506429 creator A5023129428 @default.
• W2576506429 creator A5066731966 @default.
• W2576506429 creator A5080954583 @default.
• W2576506429 date "2015-12-03" @default.
• W2576506429 modified "2023-09-27" @default.
• W2576506429 title "A Pilot Study of Mitoxantrone in Combination with Clofarabine (MITCL) in Children, Adolescents and Young Adults (CAYA) with Refractory/Relapsed Acute Leukemia" @default.
• W2576506429 doi "https://doi.org/10.1182/blood.v126.23.2499.2499" @default.
• W2576506429 hasPublicationYear "2015" @default.
• W2576506429 type Work @default.
• W2576506429 sameAs 2576506429 @default.
• W2576506429 citedByCount "0" @default.
• W2576506429 crossrefType "journal-article" @default.
• W2576506429 hasAuthorship W2576506429A5001697191 @default.
• W2576506429 hasAuthorship W2576506429A5005741602 @default.
• W2576506429 hasAuthorship W2576506429A5023129428 @default.
• W2576506429 hasAuthorship W2576506429A5066731966 @default.
• W2576506429 hasAuthorship W2576506429A5080954583 @default.
• W2576506429 hasConcept C121332964 @default.
• W2576506429 hasConcept C126322002 @default.
• W2576506429 hasConcept C141071460 @default.
• W2576506429 hasConcept C142424586 @default.
• W2576506429 hasConcept C143998085 @default.
• W2576506429 hasConcept C2776694085 @default.
• W2576506429 hasConcept C2776863199 @default.
• W2576506429 hasConcept C2777198975 @default.
• W2576506429 hasConcept C2778041864 @default.
• W2576506429 hasConcept C2778461978 @default.
• W2576506429 hasConcept C2780775027 @default.
• W2576506429 hasConcept C2780923524 @default.
• W2576506429 hasConcept C2781413609 @default.
• W2576506429 hasConcept C71924100 @default.
• W2576506429 hasConcept C87355193 @default.
• W2576506429 hasConcept C90924648 @default.
• W2576506429 hasConceptScore W2576506429C121332964 @default.
• W2576506429 hasConceptScore W2576506429C126322002 @default.
• W2576506429 hasConceptScore W2576506429C141071460 @default.
• W2576506429 hasConceptScore W2576506429C142424586 @default.
• W2576506429 hasConceptScore W2576506429C143998085 @default.
• W2576506429 hasConceptScore W2576506429C2776694085 @default.
• W2576506429 hasConceptScore W2576506429C2776863199 @default.
• W2576506429 hasConceptScore W2576506429C2777198975 @default.
• W2576506429 hasConceptScore W2576506429C2778041864 @default.
• W2576506429 hasConceptScore W2576506429C2778461978 @default.
• W2576506429 hasConceptScore W2576506429C2780775027 @default.
• W2576506429 hasConceptScore W2576506429C2780923524 @default.
• W2576506429 hasConceptScore W2576506429C2781413609 @default.
• W2576506429 hasConceptScore W2576506429C71924100 @default.
• W2576506429 hasConceptScore W2576506429C87355193 @default.
• W2576506429 hasConceptScore W2576506429C90924648 @default.
• W2576506429 hasLocation W25765064291 @default.
• W2576506429 hasOpenAccess W2576506429 @default.
• W2576506429 hasPrimaryLocation W25765064291 @default.
• W2576506429 hasRelatedWork W1522427563 @default.
• W2576506429 hasRelatedWork W1533099815 @default.
• W2576506429 hasRelatedWork W190039263 @default.
• W2576506429 hasRelatedWork W2013907298 @default.
• W2576506429 hasRelatedWork W2039694224 @default.
• W2576506429 hasRelatedWork W2115587079 @default.
• W2576506429 hasRelatedWork W2276111012 @default.
• W2576506429 hasRelatedWork W2349679547 @default.
• W2576506429 hasRelatedWork W2370782339 @default.
• W2576506429 hasRelatedWork W2548726484 @default.
• W2576506429 hasRelatedWork W2570848452 @default.
• W2576506429 hasRelatedWork W2589447549 @default.
• W2576506429 hasRelatedWork W2598189256 @default.
• W2576506429 hasRelatedWork W2757459408 @default.
• W2576506429 hasRelatedWork W2803992642 @default.
• W2576506429 hasRelatedWork W2980685687 @default.
• W2576506429 hasRelatedWork W2988830689 @default.
• W2576506429 hasRelatedWork W3131263934 @default.
• W2576506429 hasRelatedWork W747621895 @default.
• W2576506429 hasRelatedWork W2131256589 @default.
• W2576506429 isParatext "false" @default.
• W2576506429 isRetracted "false" @default.
• W2576506429 magId "2576506429" @default.
• W2576506429 workType "article" @default.